Latest & greatest articles for copd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd

101. Resilience as a concept for understanding family caregiving of adults with Chronic Obstructive Pulmonary Disease (COPD): an integrative review

Resilience as a concept for understanding family caregiving of adults with Chronic Obstructive Pulmonary Disease (COPD): an integrative review 28286662 2018 11 13 2054-1058 4 2 2017 Apr Nursing open Nurs Open Resilience as a concept for understanding family caregiving of adults with Chronic Obstructive Pulmonary Disease (COPD): an integrative review. 61-75 10.1002/nop2.63 This paper was a report of the synthesis of evidence on examining the origins and definitions of the concept of resilience (...) , investigating its application in chronic illness management and exploring its utility as a means of understanding family caregiving of adults with Chronic Obstructive Pulmonary Disease. Resilience is a concept that is becoming relevant to understanding how individuals and families live with illness, especially long-term conditions. Caregivers of adults with Chronic Obstructive Pulmonary Disease must be able to respond to exacerbations of the condition and may themselves experience cognitive imbalances. Yet

Nursing open2016 Full Text: Link to full Text with Trip Pro

102. Oxygen-Induced Hypercapnia in COPD: What is the Mechanism?

Oxygen-Induced Hypercapnia in COPD: What is the Mechanism? Oxygen-Induced Hypercapnia in COPD: What is the Mechanism? | Clinical Correlations Oxygen-Induced Hypercapnia in COPD: What is the Mechanism? September 28, 2016 By Jonathan Glatt Peer Reviewed It was my first week on the wards as a third-year medical student, and I found myself huddled with the team in a busy corner of the Bellevue ED, listening to a man cough and wheeze his way through an interview. He was an elderly patient (...) with an extensive smoking history–a lifetime of a destructive habit that had dilated and distorted his lungs beyond repair. He told us, between bouts of breathlessness, of worsening dyspnea and copious sputum production over the past couple of days, riding into his diseased alveoli on the viral coattails of a recent upper respiratory infection. Armed with a presumptive diagnosis of acute chronic obstructive pulmonary disease (COPD) exacerbation, we proceeded to manage his symptoms in full force, dilating his

Clinical Correlations2016

103. Budesonide-formoterol (Symbicort) - Treatment of patients with chronic obstructive pulmonary disease (COPD)

Budesonide-formoterol (Symbicort) - Treatment of patients with chronic obstructive pulmonary disease (COPD) Published 10 October 2016 Statement of Advice: budesonide/formoterol 200 micrograms/6 Inhalation powder and 400 micrograms/12 Inhalation powder (Symbicort Turbohaler ® ) budesonide/formoterol 200 micrograms/6 micrograms per actuation, pressurised inhalation, suspension (Symbicort ® ) (No: 1198/16) AstraZeneca UK Limited 09 September 2016 ADVICE: in the absence of a submission from (...) the holder of the marketing authorisation budesonide/formoterol inhalation powder (Symbicort Turbohaler ® ) and pressurised inhalation, suspension (Symbicort ® ) are not recommended for use within NHS Scotland. Indication under review: Treatment of patients with chronic obstructive pulmonary disease (COPD) with forced expiratory volume in 1 second (FEV 1 ) 50% to 70% predicted normal (post bronchodilator) and an exacerbation history despite regular bronchodilator therapy. The holder of the marketing

Scottish Medicines Consortium2016

104. Sleep quality disturbances and cognitive functioning in elderly patients with COPD

Sleep quality disturbances and cognitive functioning in elderly patients with COPD 27957482 2018 11 13 2312-0541 2 3 2016 Jul ERJ open research ERJ Open Res Sleep quality disturbances and cognitive functioning in elderly patients with COPD. 00054-2016 Information about the association between cognitive functions, such as copying function, and sleep disturbances in patients with chronic obstructive pulmonary disease (COPD) is lacking. This cross-sectional observational study aimed to investigate (...) the association between copying function and self-reported sleep quality disturbances and disease severity in an elderly COPD population. Cognitive function performances, assessed using the Mini-Mental State Examination, were compared in 562 ambulatory COPD patients with and without sleep disturbances; assessed using the Established Populations for Epidemiologic Studies of the Elderly questionnaire; and stratified by Global Initiative for Chronic Obstructive Lung Disease (GOLD) grades. Sleep disturbances

ERJ open research2016 Full Text: Link to full Text with Trip Pro

105. Prevalence of Osteoporosis and Its Risk Factors in Men with COPD in Qazvin

Prevalence of Osteoporosis and Its Risk Factors in Men with COPD in Qazvin application/xhtml+xml; charset=utf-8

International journal of chronic diseases2016 Full Text: Link to full Text with Trip Pro

106. Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice.

Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice. BACKGROUND: Evidence for the management of chronic obstructive pulmonary disease (COPD) comes from closely monitored efficacy trials involving groups of patients who were selected on the basis of restricted entry criteria. There is a need for randomized trials to be conducted in conditions that are closer to usual clinical practice. METHODS: In a controlled effectiveness trial conducted in 75 general practices, we (...) randomly assigned 2799 patients with COPD to a once-daily inhaled combination of fluticasone furoate at a dose of 100 μg and vilanterol at a dose of 25 μg (the fluticasone furoate-vilanterol group) or to usual care (the usual-care group). The primary outcome was the rate of moderate or severe exacerbations among patients who had had an exacerbation within 1 year before the trial. Secondary outcomes were the rates of primary care contact (contact with a general practitioner, nurse, or other health care

NEJM2016

107. A validation of the National Early Warning Score to predict outcome in patients with COPD exacerbation

A validation of the National Early Warning Score to predict outcome in patients with COPD exacerbation 27553223 2016 08 24 2016 12 15 1468-3296 72 1 2017 Jan Thorax Thorax A validation of the National Early Warning Score to predict outcome in patients with COPD exacerbation. 23-30 10.1136/thoraxjnl-2016-208436 The National Early Warning Score (NEWS), proposed as a standardised track and trigger system, may perform less well in acute exacerbation of COPD (AECOPD). This study externally validated (...) The Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK. Roderick Paul J PJ Academic Unit of Primary Care and Population Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, UK. eng Journal Article 2016 08 23 England Thorax 0417353 0040-6376 COPD Exacerbations 2016 02 02 2016 06 30 2016 07 18 2016 8 25 6 0 2016 8 25 6 0 2016 8 25 6 0 ppublish 27553223 thoraxjnl-2016-208436 10.1136/thoraxjnl-2016-208436

EvidenceUpdates2016

108. Umeclidinium bromide/Vilanterol. Anoro for COPD. No additions to efficacy just to price

Umeclidinium bromide/Vilanterol. Anoro for COPD. No additions to efficacy just to price 2015. DAR No 6: Umeclidinium bromide/Vilanterol. Anoro® for COPD - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : : : DAR No 6: Umeclidinium bromide/Vilanterol. Anoro® for COPD DAR No 6: Umeclidinium bromide/Vilanterol. Anoro® for COPD Content tools Share it No additions to efficacy, just to price Umeclidinium/vilanterol is a combination of a muscarinic

Drug and Therapeutics Bulletin of Navarre (Spain)2016

109. Umeclidinium bromide. Incruse for COPD. Very little efficacy

Umeclidinium bromide. Incruse for COPD. Very little efficacy 2015. DAR No 5: Umeclidinium bromide. Incruse® for COPD - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : : : DAR No 5: Umeclidinium bromide. Incruse® for COPD DAR No 5: Umeclidinium bromide. Incruse® for COPD Content tools Share it Very little efficacy Umeclidinium is a long acting muscarinic antagonist (LAMA) authorized for symptom relief in patients (...) with Chronic Obstructive Pulmonary Disease (COPD). They are no comparative data available with tiotropium, or with other LAMA or LABA. It has not shown to reduce the number of exacerbations. Neither does it improve quality of life or reduce the need for rescue treatment in studies lasting more than 12 weeks. There is concern on safety regarding its cardiovascular profile and the possible higher risk of pneumonia. Enviar comentario You can send us a comment or suggestion and we will respond to most frequently asked questions Competing

Drug and Therapeutics Bulletin of Navarre (Spain)2016

110. Prognostic assessment in COPD without lung function: the B-AE-D indices

Prognostic assessment in COPD without lung function: the B-AE-D indices 27103389 2016 06 01 2017 04 23 1399-3003 47 6 2016 Jun The European respiratory journal Eur. Respir. J. Prognostic assessment in COPD without lung function: the B-AE-D indices. 1635-44 10.1183/13993003.01485-2015 Several composite markers have been proposed for risk assessment in chronic obstructive pulmonary disease (COPD). However, choice of parameters and score complexity restrict clinical applicability. Our aim (...) was to provide and validate a simplified COPD risk index independent of lung function.The PROMISE study (n=530) was used to develop a novel prognostic index. Index performance was assessed regarding 2-year COPD-related mortality and all-cause mortality. External validity was tested in stable and exacerbated COPD patients in the ProCOLD, COCOMICS and COMIC cohorts (total n=2988).Using a mixed clinical and statistical approach, body mass index (B), severe acute exacerbations of COPD frequency (AE), modified

EvidenceUpdates2016

111. The inflammasome pathway in stable COPD and acute exacerbations

The inflammasome pathway in stable COPD and acute exacerbations 27730204 2018 11 13 2312-0541 2 3 2016 Jul ERJ open research ERJ Open Res The inflammasome pathway in stable COPD and acute exacerbations. 00002-2016 Chronic obstructive pulmonary disease (COPD) is characterised by pulmonary and systemic inflammation that bursts during exacerbations of the disease (ECOPD). The NLRP3 inflammasome is a key regulatory molecule of the inflammatory response. Its role in COPD is unclear. We investigated (...) the NLRP3 inflammasome status in: 1) lung tissue samples from 38 patients with stable COPD, 15 smokers with normal spirometry and 14 never-smokers; and 2) sputum and plasma samples from 56 ECOPD patients, of whom 41 could be reassessed at clinical recovery. We observed that: 1) in lung tissue samples of stable COPD patients, NLRP3 and interleukin (IL)-1β mRNA were upregulated, but both caspase-1 and ASC were mostly in inactive form, and 2) during infectious ECOPD, caspase-1, oligomeric ASC

ERJ open research2016 Full Text: Link to full Text with Trip Pro

112. Only severe COPD is associated with being underweight: results from a population survey

Only severe COPD is associated with being underweight: results from a population survey 27730201 2018 11 13 2312-0541 2 3 2016 Jul ERJ open research ERJ Open Res Only severe COPD is associated with being underweight : results from a population survey. 00051-2015 Low body mass index (BMI) and malnutrition in chronic obstructive pulmonary disease (COPD) are associated with a poor prognosis. The prevalence of underweight, as well as overweight, in severity grades of COPD is sparsely investigated (...) in studies of the general population and the associated patterns of risk factors are not well established. The aim of the present study was to determine the association between severity grades of airflow limitation in COPD, and both underweight and obesity when corrected for possible confounding factors. The study is based on pooled data from the OLIN (Obstructive Lung Disease in Northern Sweden) studies. Complete records with lung function, BMI and structured interview data were available from 3942

ERJ open research2016 Full Text: Link to full Text with Trip Pro

113. Inflammatory bowel disease and risk of mortality in COPD

Inflammatory bowel disease and risk of mortality in COPD 26869671 2016 05 02 2016 05 02 1399-3003 47 5 2016 May The European respiratory journal Eur. Respir. J. Inflammatory bowel disease and risk of mortality in COPD. 1357-64 10.1183/13993003.01945-2015 Patients with chronic obstructive pulmonary disease (COPD) have higher incidence and prevalence of other chronic inflammatory diseases, including inflammatory bowel disease (IBD). We assessed whether IBD onset increases mortality risk (...) in patients with COPD or asthma-associated COPD.Two population-based cohorts of COPD and asthma-COPD subjects were identified using the administrative health databases in Québec, Canada, 1990-2007. Death records were retrieved from the death certificate registry. Cox proportional hazards models were used to assess the impact of newly developed IBD on mortality risk.The COPD and asthma-COPD cohorts included 273 208 and 26 575 patients, respectively, of which 697 and 119 developed IBD. IBD increased the

EvidenceUpdates2016

114. Functional characterisation of bone marrow-derived mesenchymal stromal cells from COPD patients

Functional characterisation of bone marrow-derived mesenchymal stromal cells from COPD patients 27730190 2018 11 13 2312-0541 2 2 2016 Apr ERJ open research ERJ Open Res Functional characterisation of bone marrow-derived mesenchymal stromal cells from COPD patients. 00045-2015 Autologous bone marrow-derived mesenchymal stromal cells (BM-MSCs) are evaluated for clinical use in chronic obstructive pulmonary disease (COPD) patients, but it is unclear whether COPD affects BM-MSCs. To investigate (...) this, BM-MSCs from nine COPD patients and nine non-COPD age-matched controls were compared with regard to immunophenotype, growth and differentiation potential, and migration capacity. Other functional assays included the response to pro-inflammatory stimuli and inducers of the nuclear factor (erythroid derived 2)-like 2 antioxidant response element (Nrf2-ARE) pathway, and effects on NCI-H292 airway epithelial cells. No significant differences were observed in terms of morphology, proliferation

ERJ open research2016 Full Text: Link to full Text with Trip Pro

115. Another Choice for Prevention of COPD Exacerbations.

Another Choice for Prevention of COPD Exacerbations. Another Choice for Prevention of COPD Exacerbations. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27181835 Format MeSH and Other Data E-mail Subject (...) Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Jun 9;374(23):2284-6. doi: 10.1056/NEJMe1604444. Epub 2016 May 15. Another Choice for Prevention of COPD Exacerbations. 1 . 1 From the Division of Pulmonary Diseases and Critical Care Medicine, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill. Comment on [N Engl J Med. 2016] PMID: 27181835 DOI

NEJM2016

116. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.

Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. BACKGROUND: Most guidelines recommend either a long-acting beta-agonist (LABA) plus an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice treatment for patients with chronic obstructive pulmonary disease (COPD) who have a high risk of exacerbations. The role of treatment with a LABA-LAMA regimen in these patients is unclear. METHODS: We conducted a 52-week, randomized, double-blind, double (...) -dummy, noninferiority trial. Patients who had COPD with a history of at least one exacerbation during the previous year were randomly assigned to receive, by inhalation, either the LABA indacaterol (110 μg) plus the LAMA glycopyrronium (50 μg) once daily or the LABA salmeterol (50 μg) plus the inhaled glucocorticoid fluticasone (500 μg) twice daily. The primary outcome was the annual rate of all COPD exacerbations. RESULTS: A total of 1680 patients were assigned to the indacaterol-glycopyrronium

NEJM2016

117. Smoking, Not COPD, as the Disease.

Smoking, Not COPD, as the Disease. Smoking, Not COPD, as the Disease. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27168438 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard (...) Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 May 12;374(19):1885-6. doi: 10.1056/NEJMe1515508. Smoking, Not COPD, as the Disease. 1 . 1 From Dipartimento di Medicina Metabolica, Nuovo Ospedale Civile Sant'Agostino Estense, Azienda Unitá Sanitaria Locale di Modena, Azienda Ospedaliero-Universitaria Policlinico di Modena, Università degli Studi di Modena e Reggio Emilia, Modena, Italy. Comment on [N Engl

NEJM2016

118. Measurement duration impacts variability but not impedance measured by the forced oscillation technique in healthy, asthma and COPD subjects

Measurement duration impacts variability but not impedance measured by the forced oscillation technique in healthy, asthma and COPD subjects 27730194 2018 11 13 2312-0541 2 2 2016 Apr ERJ open research ERJ Open Res Measurement duration impacts variability but not impedance measured by the forced oscillation technique in healthy, asthma and COPD subjects. 00094-2015 The forced oscillation technique (FOT) is gaining clinical acceptance, facilitated by more commercial devices and clinical data (...) . However, the effects of variations in testing protocols used in FOT data acquisition are unknown. We describe the effect of duration of data acquisition on FOT results in subjects with asthma, chronic obstructive pulmonary disease (COPD) and healthy controls. FOT data were acquired from 20 healthy, 22 asthmatic and 18 COPD subjects for 60 s in triplicate. The first 16, 30 and 60 s of each measurement were analysed to obtain total, inspiratory and expiratory resistance of respiratory system ( R rs

ERJ open research2016 Full Text: Link to full Text with Trip Pro

119. Increasing burden of COPD in rural India: an example why India warrants primary healthcare reforms

Increasing burden of COPD in rural India: an example why India warrants primary healthcare reforms 27730188 2018 11 13 2312-0541 2 2 2016 Apr ERJ open research ERJ Open Res Increasing burden of COPD in rural India: an example why India warrants primary healthcare reforms. 00032-2016 Battle against COPD: time to reinforce the primary healthcare units of rural areas of India to combat lung diseases http://ow.ly/ZAwge. Kalkana Toshita T Dept of Pneumology, Allergy and Asthma Research Centre

ERJ open research2016 Full Text: Link to full Text with Trip Pro

120. Home health monitoring compared with usual care for patients with moderate to severe COPD

Home health monitoring compared with usual care for patients with moderate to severe COPD

SHTG Advice Statements2016